NMD Pharma has recently published positive Phase 1/2a data in the journal Science Translational Medicine, establishing the first clinical proof-of-mechanism of CIC-1 inhibitors in patients ...

NMD Pharma A/S Thomas Holm Pedersen, CEO E-mail: [email protected] ICR Consilium Mary-Jane Elliott / Ashley Tapp / Lindsey Neville E-mail: [email protected] Tel: +44 (0)20 3709 5700 ...

Chasing Big Pharma rivals, NMD posts clinical data on rare disease prospect By Nick Paul Taylor Oct 11, 2022 6:48am Myasthenia Gravis clinical trial data muscle function Clinical Data ...

NMD Pharma Oct 03, 2023, 7:00 AM ET NMD Pharma to present NMD670 clinical data from a Phase I/IIa trial in myasthenia gravis at the 28th International Annual Congress of the World Muscle Society ...

NMD Pharma also has a number of employees who are affiliated with Aarhus University. These employees work on both research and development projects.

NMD Pharma will be also presenting new clinical data from the Phase I/IIa trial of NMD670 in patients with MG in a poster presentation at the conference, which follows the announcement of positive ...

News provided by NMD Pharma May 23, 2023, 7:00 AM ET NMD Pharma initiates Phase I safety, tolerability and pharmacokinetics studyof NMD1343 NMD1343 is a novel small molecule inhibitor of the ...